Financial Data and Key Metrics Changes - In Q4 2025, Crinetics Pharmaceuticals recognized $6.2 million in total net revenue, comprising $5.4 million from the U.S. commercial launch of PALSONIFY and $0.8 million from a licensing agreement with SKK in Japan [26] - Total revenue for the full year 2025 was $7.7 million, with a cost of product revenue of $1.1 million in Q4 [26][27] - The company ended 2025 with over $1 billion in cash equivalents and investments, excluding $380 million from a public offering in January 2026, bringing total cash equivalents to approximately $1.4 billion post-offering [29][30] Business Line Data and Key Metrics Changes - The launch of PALSONIFY has seen over 200 enrollment forms received in Q4, with more than 125 unique prescribers involved [8][9] - The company is focusing on building a commercial enterprise around PALSONIFY, with a fully integrated team in place to support its launch [10][11] Market Data and Key Metrics Changes - The company is experiencing encouraging formulary momentum with payers, securing wins with top plans in the U.S. for PALSONIFY [9] - Approximately 50% of claims have been pre-reimbursed, with 60% moving into a Quick Start program [64] Company Strategy and Development Direction - Crinetics is transitioning from building a pipeline to building a business, aiming to establish itself as a leading endocrinology company [7] - The company is focused on launching multiple innovative pharmaceuticals from its pipeline, including paltusotine and Atumelnant, while also advancing its nonpeptide drug conjugate program [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for PALSONIFY and the potential for Atumelnant to address significant unmet needs in treating Cushing's disease [11][25] - The company anticipates that existing cash and investments will be sufficient to fund operations into 2030, allowing for continued investment in clinical trials and commercialization activities [30] Other Important Information - The company has received a positive CHMP opinion for PALSONIFY in the treatment of acromegaly, marking a significant milestone for its European regulatory path [32] - The EQUILIBRIUM ADCS study is designed to efficiently assess the safety and efficacy of Atumelnant in treating ACTH-dependent Cushing's syndrome [25] Q&A Session Summary Question: Insights from phase II/III design and previous studies - Management noted that the structure of the Cushing's disease study is well precedented, with normalization of urine-free cortisol as a primary endpoint [34][37] Question: Trends in PALSONIFY prescriptions - Management expressed satisfaction with the launch and noted positive feedback from prescribers and patients, but refrained from providing specific quantitative trends [41][42] Question: Enrollment forms and commercial therapy timeline - Management indicated that it is premature to extrapolate the 200 enrollment forms as a run rate, and about 50% of patients are reimbursed for commercial therapy [49][50] Question: Payer dynamics for PALSONIFY - Management reported positive progress in market access with no significant barriers to treatment, and ongoing engagement with payers [63][64] Question: ADCS study design and endpoints - Management confirmed that the primary endpoint for the phase III study is set by the FDA, focusing on the percentage of patients achieving normal urine-free cortisol [68][69]

February 26, 2026 Fourth Quarter and Full Year 2025 Financial Results and Business Update Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: our ability to effectively comme ...

Company Overview - Amprius Technologies specializes in high-energy-density, high-capacity lithium-ion batteries utilizing silicon anodes, positioning itself to lead in the electric power economy shift [2][6] - The company claims to offer batteries with the highest energy density on the market, long life cycles, and ultra-fast charging times, while ensuring safety through rigorous testing [1][6] Financial Performance - In its 3Q25 report, Amprius reported a record revenue of $21.4 million, exceeding forecasts by $4.6 million, and reflecting a 172% year-over-year increase [8] - The company experienced a net loss of 3 cents per share, which was better than expected, and its stock has risen 187.5% over the past 12 months [8] Product Features - Amprius batteries provide 100% longer running times, operate within a temperature range of -30 to +60 degrees Celsius, support over 1,300 lifetime charge cycles, and can charge to 80% capacity in just 6 minutes [6] - The batteries are designed for diverse applications, including manned and unmanned aircraft, light electric vehicles, and AI and robotics [6] Leadership Transition - As of January 1, Tom Stepien has taken over as CEO, transitioning from his previous role as President, while former CEO Dr. Kang Sun remains as an Executive Advisor [7] Market Position and Strategy - Analyst Colin Rusch notes that Amprius is entering a new phase with a focus on long-term pricing strategies and has over 2GWh of manufacturing capacity, which aligns with the US National Defense Authorization Act [9] - The company is expected to announce significant new customers, leveraging its lead in high-density, lightweight battery technology for aerospace and defense applications [9] Analyst Ratings - Rusch rates AMPX stock as Outperform (Buy) with a price target of $17, indicating a potential one-year gain of 67.5% [10] - The stock has a Strong Buy consensus based on 7 positive reviews, with an average target price suggesting a 69% upside [10]

JANUARY 2026 Beyond Innovation to Impact: Building the Premier Endocrinology Business J.P. Morgan Healthcare Conference Angela Living with Acromegaly Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forw ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Crinetics Pharmaceuticals Conference Call Summary Company Overview - **Company**: Crinetics Pharmaceuticals (NasdaqGS:CRNX) - **Date**: January 05, 2026 - **Key Products**: Palsonify (for acromegaly), Atumelnant (for congenital adrenal hyperplasia, CAH) Key Points Industry and Market Context - The call discussed the acromegaly market, highlighting approximately **36,000 people** living with the condition in the U.S. [7] - The company aims to address the challenges faced by patients with acromegaly, many of whom have been stalled by inconsistent treatments [7] Product Launch and Performance - **Palsonify**: - Launched successfully in Q4 2025, with over **200 enrollment forms** processed [12] - Achieved **$5 million** in unaudited net revenue for the fourth quarter [12] - The launch strategy focuses on engaging both actively managed patients and those who have not been diagnosed [9] - Positive patient feedback has been reported, with many switching from injectable therapies to Palsonify [10] - **Atumelnant**: - Positioned to transform CAH treatment, aiming to provide a new standard of care without the side effects of high-dose steroids [5] - Data indicates a robust benefit-risk profile, with ongoing phase three studies planned [6] - The drug is designed to selectively block the ACTH receptor, potentially leading to significant reductions in adrenal androgens [17] Clinical Data and Studies - **Atumelnant Phase 2 Study**: - Cohort four results showed sustained reductions in androstenedione (A4) levels while tapering glucocorticoids [22] - A4 reductions were observed even with glucocorticoid doses reduced to physiological levels [24] - The study demonstrated a **67% reduction** in A4 levels in cohort four [33] - **Safety Profile**: - Atumelnant has been well tolerated with no serious adverse events reported across over **750 weeks** of patient exposure [30] - Common adverse events included headache and fatigue, typical for this patient population [29] Future Plans and Expectations - The company is optimistic about the upcoming **phase 3 CALM CAH study**, targeting **150 patients** to evaluate Atumelnant's safety and efficacy [30] - The study aims to demonstrate a statistically significant difference in achieving normal A4 levels while on physiological glucocorticoid doses [31] - Crinetics plans to continue expanding its pipeline, with additional candidates like paltusotine for carcinoid syndrome and CRN9682 for SST2-expressing cancers [36] Commercial Strategy - The company emphasizes commercial execution as a top priority, with a focus on building relationships with healthcare providers and payers [11] - Early formulary inclusions have been secured, and the company is actively engaging with payers to ensure patient access [12][70] Additional Insights - The company is committed to addressing the long diagnostic delays for acromegaly, which can take **5 to 10 years** [9] - The patient ambassador program aims to leverage patient experiences to enhance awareness and support for Palsonify [13] Conclusion Crinetics Pharmaceuticals is positioned for growth in the endocrine treatment market, with successful product launches and promising clinical data for Atumelnant. The company is focused on improving patient outcomes and expanding its market presence through strategic commercial initiatives and ongoing clinical studies.

Core Points - Crinetics Pharmaceuticals granted stock options and RSUs to 20 new non-executive employees as part of its 2021 Inducement Plan to attract talent [1][2] - The stock options have an exercise price of $35.00 per share, equal to the closing price on September 10, 2025, and will vest over four years [2] - Crinetics is a clinical-stage pharmaceutical company focused on developing therapeutics for endocrine diseases and related tumors, with its lead candidate being PALSONIFY™ for acromegaly [3] Summary by Category Stock Options and RSUs - The Compensation Committee granted a total of 62,475 stock options and 43,800 RSUs under the 2021 Inducement Plan [1] - Stock options will vest over four years, with 25% vesting after one year and the remainder in 36 equal monthly installments [2] - RSUs will also vest over four years in equal annual installments starting from the one-year anniversary of the vesting commencement date [2] Company Overview - Crinetics Pharmaceuticals specializes in discovering and developing novel therapeutics for endocrine diseases and tumors [3] - The company’s lead candidate, PALSONIFY™, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3] - Other development programs include treatments for congenital adrenal hyperplasia, Cushing's syndrome, and various endocrine conditions [3]

Core Points - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan [1][2] - A total of 75,850 stock options and 53,400 RSUs were awarded, aimed at attracting talent to the company [1] - The stock options have an exercise price of $26.85 per share, equal to the closing price on August 8, 2025, and will vest over four years [2] Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing therapeutics for endocrine diseases and related tumors [3] - The lead candidate, PALSONIFY (paltusotine), is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3] - Other drug candidates include Atumelnant, targeting congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with a focus on orally delivered small molecules [3]

Group 1 - Crinetics Pharmaceuticals, Inc. will report its second quarter 2025 financial results on August 7, 2025, after market close [1] - A conference call will be held at 4:30 p.m. ET on the same day to discuss the financial results and provide a business update [1][2] - The conference call can be accessed via dial-in numbers or a live webcast, with a recommendation to connect 15 minutes prior to the start [2] Group 2 - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors [4] - The lead development candidate, PALSONIFY (paltusotine), is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [4] - Other drug candidates include Atumelnant, which is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with all candidates being orally delivered small molecules [4]